Search results for "CEF"

showing 10 items of 318 documents

Fatal Anaphylactic Shock Ceftriaxone-Induced in a 4-Year-Old Child

2014

One of the most used cephalosporin in clinical practice is ceftriaxone. Anaphylaxis due to the administration of ceftriaxone is considered a rare event. Here, we report a case of fatal anaphylactic shock after the administration of ceftriaxone in a child who had tolerated the drug in past exposures. The allergic pathogenesis is sustained by the clinical data (short time between the inoculation of the drug and the onset of the symptoms; past exposure to the same molecule and probable sensitization) and the postmortem examination findings (polivisceral congestion and intense eosinophilia found in the histological examination).

Malemedicine.medical_specialtymedicine.drug_classCephalosporinDrug Hypersensitivity03 medical and health sciencesFatal Outcome0302 clinical medicineHumansMedicineEosinophilia030216 legal & forensic medicineAnaphylaxisSensitizationRetrospective StudiesHistological examination030201 allergybusiness.industryCeftriaxoneRetrospective cohort studyGeneral Medicinemedicine.diseaseDermatologyAnti-Bacterial Agentsmedicine.anatomical_structureChild PreschoolPediatrics Perinatology and Child HealthEmergency MedicineCeftriaxoneAnaphylactic shockAutopsymedicine.symptombusinessAnaphylaxismedicine.drugPediatric Emergency Care
researchProduct

Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis.

2011

The aim of this study was to define a two-compartments pharmacokinetic model and to estimate the pharmacokinetic parameters of IP administered vancomycin in patients with continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis. Ten patients with peritoneal dialysis treatment and peritonitis were prospectively enrolled in the study. The empiric treatment is: vancomycin 2 g every 5-7 days and ceftazidime 1500 mg per exchange, once daily. Pharmacokinetic modeling and parameter calculations were carried out using the nonlinear regression. The mean peritoneal concentration 10 min after the first peritoneal exchange of vancomycin free dialysis liquid was 9.5±7.3 μg/ml, showing tha…

Malemedicine.medical_specialtymedicine.medical_treatmentUrologyPharmaceutical SciencePeritonitisPeritonitisCeftazidimePeritoneal dialysisPharmacokineticsPeritoneal Dialysis Continuous AmbulatoryVancomycinmedicineHumansDialysisAntibacterial agentAgedbusiness.industryContinuous ambulatory peritoneal dialysisMiddle Agedmedicine.diseaseSurgeryAnti-Bacterial AgentsAmbulatoryVancomycinFemalebusinessInjections Intraperitonealmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Il mare e la città. Cefalù e il Parco delle mura megalitiche di Pasquale Culotta, Giuseppe Leone e Tania Culotta.

2019

Il Mediterraneo è una delle fonti dell’architettura tout court ed è all’origine della storia dell’abitare del Vecchio Mondo. Al ruolo costante e di fondazione del Mare Nostrum si collega, diversi millenni dopo, quello avuto come impulso all’architettura contemporanea e, in particolare, al Movimento Moderno. Su tale imprescindibile rapporto si innesta una specifica questione relativa alle città costiere e al modo in cui queste abbiano concretamente declinato l’interazione con il mare. Se l’arco cronologico si restringe dal secondo dopoguerra ad oggi, molti di questi rapporti sono occasioni mancate, incontri distratti, dove le coste, al pari dei fondi agricoli, sono state considerate, in modo…

Mediterráneo arquitectura ciudades costeras Cefalú Pasquale Culotta Giuseppe Leone Tania Culotta Casa Salem Cortina Megalítica plano paisajístico de la Rocca.Settore ICAR/14 - Composizione Architettonica E UrbanaMediterranean sea architecture coastal cities Cefalù Pasquale Culotta Giuseppe Leone Tania Culotta Salem house Megalithic walls landscape Plan of the Rocca.Mediterraneo architettura città costiere Cefalù Pasquale Culotta Giuseppe Leone Tania Culotta casa Salem cortina Megalitica piano paesistico della Rocca.
researchProduct

Ruolo dell’imaging di Risonanza Magnetica nella valutazione del controllo della risposta al trattamento radiochirurgico delle metastasi encefaliche

2017

Metastasi encefaliche rediochirurgia stereotassica RM
researchProduct

Ceftazidime-avibactam use for klebsiella pneumoniae carbapenemase-producing k. pneumoniae infections: A retrospective observational multicenter study

2021

Abstract Background A growing body of observational evidence supports the value of ceftazidime-avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant Enterobacteriaceae. Methods We retrospectively analyzed observational data on use and outcomes of CAZ-AVI therapy for infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae (KPC-Kp) strains. Multivariate regression analysis was used to identify variables independently associated with 30-day mortality. Results were adjusted for propensity score for receipt of CAZ-AVI combination regimens versus CAZ-AVI monotherapy. Results The cohort comprised 577 adults with bloodstream infections (n = 391) or nonba…

Microbiology (medical)Adultmedicine.medical_specialtyAzabicyclo CompoundcarbapenemasesBacterial ProteinMicrobial Sensitivity TestsNeutropeniaCeftazidimebeta-Lactamasesbeta-LactamaseCarbapenemasecarbapenemaseBacterial ProteinsRetrospective StudieLower respiratory tract infectionInternal medicineDrug CombinationAnti-Bacterial AgentmedicineHumansKPC-producing Klebsiella pneumoniaeRetrospective StudiesSeptic shockbusiness.industryCeftazidime-avibactamMicrobial Sensitivity Testceftazidime-avibactamMortality rateCarbapenemases; Ceftazidime-avibactam; KPC-producing Klebsiella pneumoniae; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeKPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactammedicine.diseaseCeftazidime/avibactamSettore MED/17KPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactam; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeAnti-Bacterial AgentsKlebsiella InfectionsDrug CombinationsKlebsiella pneumoniaeInfectious DiseasesCohortPropensity score matchingObservational studybusinessAzabicyclo Compoundsmedicine.drugHumanKlebsiella Infection
researchProduct

Combination of aztreonam, ceftazidime–avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis

2021

Abstract We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the blaVIM-1 gene and belonged to the high-risk clone sequence type ST235. The patient was successfully treated with surgical debridement plus antibiotic therapy with ceftazidime/avibactam, aztreonam, and amikacin. Time-kill curves showed that this triple antibiotic combination at 1 × MIC was strongly synergic after 8 h, achieving 99.9% killing and maintaining this until 48 h.

Microbiology (medical)AvibactamDrug ResistanceCeftazidimeInfectious and parasitic diseasesRC109-216Aztreonammedicine.disease_causeST235CeftazidimeMicrobiologyCeftazidime–avibactamchemistry.chemical_compoundAztreonamAortic valve replacementDrug TherapyDrug Resistance Multiple BacterialmedicineHumansPseudomonas InfectionsPseudomonas aeruginosa; ST235; VIM-1; aztreonam; ceftazidime-avibactam; osteomyelitisAmikacinAgedPseudomonas aeruginosabusiness.industryceftazidime-avibactamOsteomyelitisBacterialOsteomyelitisGeneral MedicineCeftazidime/avibactammedicine.diseaseAnti-Bacterial AgentsDrug CombinationsInfectious DiseaseschemistryDebridementAmikacinPseudomonas aeruginosaCombinationVIM-1Drug Therapy CombinationFemalebusinessAzabicyclo CompoundsMultiplemedicine.drug
researchProduct

Infection of the upper extremity by Mycobacterium marinum in a 3-year-old boy--diagnosis by 16S-rDNA analysis.

1996

A 3-year-old boy developed several subcutaneous nodular lesions on his right arm. Based on the histological examination of one of these nodules furunculosis was suspected and cefuroxime was tentatively given. However, acid-fast bacilli were then detected in the tissue specimen and a few colonies of acid fast, gram-positive rods grew on blood agar. Definitive species diagnosis (Mycobacterium marinum) was rapidly achieved by automated sequencing of amplified 16S-rDNA and antimicrobial therapy was adjusted according to the available literature. After 3 weeks of treatment with clarithromycin, rifampicin and protionamid regression of the nodular lesions was evident.

Microbiology (medical)DNA BacterialMalePathologymedicine.medical_specialtyDNA RibosomalMycobacteriumAgar plateClarithromycinRNA Ribosomal 16SmedicineHumansMycobacterium marinumMycobacterium Infectionsbiologybusiness.industryNodule (medicine)General Medicinebiology.organism_classificationInfectious DiseasesChild PreschoolArmmedicine.symptombusinessCefuroximeRifampicin16s rdna analysismedicine.drugMycobacteriumInfection
researchProduct

New β-Lactam-β-Lactamase Inhibitor Combinations.

2020

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam-β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa Ceftazidime-avibactam is a potential drug for treating Enterobacterales producing extended-spectrum β-lactamase (ESBL), Klebsiella pneumoniae carbapenemase (KPC), AmpC, an…

Microbiology (medical)DrugImipenemBacilliEpidemiologyKlebsiella pneumoniaemedia_common.quotation_subjectMicrobial Sensitivity Testsmedicine.disease_causebeta-LactamsMeropenemMicrobiologyDrug Resistance Multiple BacterialGram-Negative Bacteriapolycyclic compoundsmedicinemedia_commonGeneral Immunology and MicrobiologybiologyPseudomonas aeruginosabusiness.industryPublic Health Environmental and Occupational Healthbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationCeftazidime/avibactamAcinetobacter baumanniiDrug CombinationsInfectious DiseasesbacteriaErratumbusinessbeta-Lactamase Inhibitorsmedicine.drugClinical microbiology reviews
researchProduct

Mobilisation of plasmid-mediated blaVEB-1 gene cassette into distinct genomic islands of Proteus mirabilis after ceftazidime exposure

2021

ABSTRACT Objectives We sought to integrate a VEB-1-encoding gene cassette into the integron of the MDR region of genomic islands (GIs) harboured by Proteus mirabilis strains after antibiotic exposure. Methods An IncP1 plasmid from Achromobacter xylosoxidans carrying the cassette array dfrA14–blaVEB-1–aadB was introduced by conjugation into five strains of P. mirabilis: PmBRI, PmABB, PmSCO and Pm2CHAMA harbouring Salmonella GI 1 and PmESC harbouring Proteus GI 1. Circular intermediates of the cassettes were amplified by PCR. blaVEB-harbouring P. mirabilis were exposed to increasing concentrations of ceftazidime each day. Presence of blaVEB-1 in the GI was assessed by PCR. The complete MDR re…

Microbiology (medical)ImmunologyCeftazidimeAchromobacter xylosoxidansBiologyIntegronbiology.organism_classificationProteus mirabilisMicrobiologyblaVEB-1Cassette arrayQR1-502MicrobiologyIncP1ProteusPlasmidGene cassetteClass 1 integronbiology.proteinmedicineImmunology and AllergyGeneSGI1medicine.drugPGI1Journal of Global Antimicrobial Resistance
researchProduct

In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneum…

2008

In this study, we compared the efficacy of ceftazidime (CAZ) intermittent versus continuous infusion with or without tobramycin (TOB) for the treatment of pneumonia caused by Pseudomonas aeruginosa in rabbits. Treatments were humanised and mimicked intermittent CAZ (iCAZ) (2g three times daily), continuous CAZ (cCAZ) (4g once daily (qd)) and TOB (10mg/kg qd). Minimum inhibitory concentrations (MICs) were 1mg/L and 4mg/L for TOB and CAZ, respectively. Bacterial efficacy in lungs was as follows: control, 9+/-0.6 colony-forming units (CFU)/g; TOB monotherapy, 8+/-0.5CFU/g; iCAZ monotherapy, 7.8+/-1.4CFU/g; cCAZ monotherapy, 8+/-0.4CFU/g (P = 0.005); and iCAZ+TOB, 8+/-0.5CFU/g; cCAZ+TOB, 7.2+/-…

Microbiology (medical)Malemedicine.drug_classAntibioticsColony Count MicrobialCeftazidimeMicrobial Sensitivity TestsCeftazidimeMicrobiologyPseudomonas infectionmedicineTobramycinPneumonia BacterialAnimalsHumansPharmacology (medical)Pseudomonas InfectionsInfusions IntravenousLungAntibacterial agentProtein synthesis inhibitorbusiness.industryAminoglycosideGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesPharmacodynamicsTobramycinDrug Therapy CombinationRabbitsbusinessSpleenmedicine.drugInternational journal of antimicrobial agents
researchProduct